Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677300 · ClinicalTrials.gov registry record · Phase 4
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
A Phase 4 study, sponsored by Dallas VA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 85
- Enrollment target
NCT00677300: Completed Phase 4 study, sponsored by Dallas VA Medical Center.
NCT00677300 is a Phase 4 study that has completed, run by Dallas VA Medical Center. The registered enrollment target is 85 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00677300, a Phase 4 study, has completed, sponsored by Dallas VA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a combination of raltegravir and darunavir is as effective as standard regimens in the treatment of HIV-infected patients who have not previously used antiretroviral drug (treatment naive)
Interventions
- DRUG Ritonavir
- DRUG Raltegravir
- DRUG Darunavir
- DRUG Tenofovir/Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT00677300 record still lists
NCT00677300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00677300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00677300 about?
NCT00677300 is a clinical study titled "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients". The purpose of this study is to determine whether a combination of raltegravir and darunavir is as effective as standard regimens in the treatment of HIV-infected patients who have not previously used antiretroviral drug (treatment naive)
What is the current status of trial NCT00677300?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2009-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00677300?
The interventions under investigation include: Ritonavir (DRUG), Raltegravir (DRUG), Darunavir (DRUG), Tenofovir/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00677300?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00677300's enrollment target sits among peer trials
85 928th of 2000 higher than 1,072 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia